Research Article
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
Table 3
Differences of a gene in patients with different curative effects before treatment.
| | Pathway | Gene count | Gene |
| | Upregulated | Helper_T_cells | 1 | GATA3 | | Lymphocyte_development | 1 | IKZF2 | | Chemokine_signaling | 1 | VEGFA |
| | Downregulated | Tumor_marker | 3 | TP63, MMP9, EGR3 | | Antigen_processing | 2 | HLA-F-AS1, HLA-A | | Type_I_interferon_signaling | 2 | IFITM1, IFIT1 | | Dendritic_cell | 1 | HERC6 | | Lymphocyte_infiltrate | 1 | TAGAP | | T_cell_differentiation | 1 | EGR2 | | Checkpoint_pathway | 1 | LAG3 | | Type_II_interferon_signaling | 1 | CXCL10 |
|
|
